Michael W. Kalb - 20 Nov 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Executive Vice President & CFO
Signature
/s/ Michael W. Kalb
Issuer symbol
CPRX
Transactions as of
20 Nov 2025
Net transactions value
$0
Form type
4
Filing time
24 Nov 2025, 20:08:32 UTC
Previous filing
03 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kalb Michael Wayne Executive Vice President & CFO 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Michael W. Kalb 24 Nov 2025 0001678248

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +6,894 +164% 11,091 21 Nov 2025 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -2,485 -22% 8,606 21 Nov 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Award $0 +131,536 +28% $0.000000 607,235 20 Nov 2025 Common Stock 131,536 $22.77 Direct F3
transaction CPRX Restricted Stock Units Award $0 +39,701 +6.5% $0.000000 646,936 20 Nov 2025 Common Stock 39,701 Direct F3, F4
transaction CPRX Restricted Stock Units Options Exercise $0 -6,894 -1.1% $0.000000 640,042 21 Nov 2025 Common Stock 6,894 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
F3 Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
F4 Shares of common stock will be delivered to the Reporting Person upon vesting.
F5 Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
F6 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.